CN114533765B - 短双歧杆菌ccfm1025在调节幼年神经发育中的应用 - Google Patents
短双歧杆菌ccfm1025在调节幼年神经发育中的应用 Download PDFInfo
- Publication number
- CN114533765B CN114533765B CN202210265577.XA CN202210265577A CN114533765B CN 114533765 B CN114533765 B CN 114533765B CN 202210265577 A CN202210265577 A CN 202210265577A CN 114533765 B CN114533765 B CN 114533765B
- Authority
- CN
- China
- Prior art keywords
- ccfm1025
- bifidobacterium breve
- development
- nerve
- intestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186012 Bifidobacterium breve Species 0.000 title claims abstract description 35
- 230000001105 regulatory effect Effects 0.000 title abstract description 10
- 230000030363 nerve development Effects 0.000 title abstract description 7
- 230000000366 juvenile effect Effects 0.000 title abstract description 6
- 230000008774 maternal effect Effects 0.000 claims abstract description 8
- 210000004126 nerve fiber Anatomy 0.000 claims abstract description 7
- 230000035935 pregnancy Effects 0.000 claims abstract description 6
- 230000019771 cognition Effects 0.000 claims abstract description 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 claims description 5
- 241000186000 Bifidobacterium Species 0.000 claims description 5
- 101800003906 Substance P Proteins 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 3
- 208000019022 Mood disease Diseases 0.000 claims description 3
- 230000005176 gastrointestinal motility Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- 206010067601 Dysmyelination Diseases 0.000 claims 1
- 102100024304 Protachykinin-1 Human genes 0.000 claims 1
- 235000020299 breve Nutrition 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 238000005204 segregation Methods 0.000 claims 1
- 230000023105 myelination Effects 0.000 abstract description 16
- 230000000968 intestinal effect Effects 0.000 abstract description 14
- 238000011161 development Methods 0.000 abstract description 11
- 230000018109 developmental process Effects 0.000 abstract description 11
- 230000006870 function Effects 0.000 abstract description 11
- 239000006041 probiotic Substances 0.000 abstract description 9
- 235000018291 probiotics Nutrition 0.000 abstract description 9
- 210000000653 nervous system Anatomy 0.000 abstract description 7
- 230000008855 peristalsis Effects 0.000 abstract description 7
- 208000012902 Nervous system disease Diseases 0.000 abstract description 4
- 101500013104 Pelophylax ridibundus Secretoneurin Proteins 0.000 abstract description 4
- 244000005700 microbiome Species 0.000 abstract description 3
- 235000005911 diet Nutrition 0.000 abstract description 2
- 230000037213 diet Effects 0.000 abstract description 2
- 230000008451 emotion Effects 0.000 abstract description 2
- 230000036541 health Effects 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 238000009412 basement excavation Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 34
- 239000000047 product Substances 0.000 description 17
- 102000006386 Myelin Proteins Human genes 0.000 description 15
- 108010083674 Myelin Proteins Proteins 0.000 description 15
- 210000005012 myelin Anatomy 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 11
- 210000005036 nerve Anatomy 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 210000001072 colon Anatomy 0.000 description 8
- 235000021107 fermented food Nutrition 0.000 description 8
- 210000001061 forehead Anatomy 0.000 description 7
- 210000004248 oligodendroglia Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010058314 Dysplasia Diseases 0.000 description 6
- 101000582994 Homo sapiens Myelin regulatory factor Proteins 0.000 description 6
- 102100038808 Transcription factor SOX-10 Human genes 0.000 description 6
- 230000001149 cognitive effect Effects 0.000 description 6
- 230000002550 fecal effect Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010016100 Faeces discoloured Diseases 0.000 description 5
- 101000664703 Homo sapiens Transcription factor SOX-10 Proteins 0.000 description 5
- 102100030372 Myelin regulatory factor Human genes 0.000 description 5
- 235000012055 fruits and vegetables Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108700039887 Essential Genes Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102100021831 Myelin-associated glycoprotein Human genes 0.000 description 4
- 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 4
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 4
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 102400000096 Substance P Human genes 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 210000003007 myelin sheath Anatomy 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000000535 oligodendrocyte precursor cell Anatomy 0.000 description 3
- 210000002442 prefrontal cortex Anatomy 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- 240000007087 Apium graveolens Species 0.000 description 2
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 2
- 235000010591 Appio Nutrition 0.000 description 2
- 235000016068 Berberis vulgaris Nutrition 0.000 description 2
- 241000335053 Beta vulgaris Species 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 2
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 2
- 240000008067 Cucumis sativus Species 0.000 description 2
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- 102000047918 Myelin Basic Human genes 0.000 description 2
- 101710107068 Myelin basic protein Proteins 0.000 description 2
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 description 2
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 2
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 2
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000015142 cultured sour cream Nutrition 0.000 description 2
- 230000007267 depressive like behavior Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 210000000105 enteric nervous system Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000026781 habituation Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000008991 intestinal motility Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007087 memory ability Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101000876511 Homo sapiens General transcription and DNA repair factor IIH helicase subunit XPD Proteins 0.000 description 1
- 101000616778 Homo sapiens Myelin-associated glycoprotein Proteins 0.000 description 1
- 101001115699 Homo sapiens Myelin-oligodendrocyte glycoprotein Proteins 0.000 description 1
- -1 MBP) Proteins 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 101710176133 Transcription factor Sox-10 Proteins 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006400 anxiety behaviour Effects 0.000 description 1
- 230000007529 anxiety like behavior Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000028315 developmental maturation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000002563 stool test Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960002197 temoporfin Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C13/00—Cream; Cream preparations; Making thereof
- A23C13/12—Cream preparations
- A23C13/16—Cream preparations containing, or treated with, microorganisms, enzymes, or antibiotics; Sour cream
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
- A23C19/061—Addition of, or treatment with, microorganisms
- A23C19/062—Addition of, or treatment with, microorganisms using only lactic acid bacteria, e.g. pediococcus, leconostoc or bifidus sp., or propionic acid bacteria; Treatment with non-specified acidifying bacterial cultures
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了短双歧杆菌CCFM1025在调节幼年神经发育中的应用,属于微生物技术领域。所述短双歧杆菌CCFM1025通过母体妊娠期干预,能够减轻生命早期应激下子代小鼠的神经系统过度髓鞘化,恢复正常的神经发育,并进而保护情绪、认知,调节肠道正常蠕动,修复肠道神经纤维正常释放肠脑肽的能力,对于深入挖掘益生菌的功能,开发具有更高保健价值的益生菌具有十分重要的意义,也为利用膳食策略预防神经系统疾病开辟出新的途径和解决方案。
Description
技术领域
本发明涉及短双歧杆菌CCFM1025在调节幼年神经发育中的应用,属于微生物技术领域。
背景技术
幼年是神经系统发育最重要的窗口期。胎儿的大脑发育过程中,每分钟约有25万个神经元生成;新生儿神经元数量较少,随后迅速增长,到两岁即可达到成年人的水平。生命早期应激可以增加神经发育障碍的发生风险,可诱发包括重度抑郁症、创伤后应激障碍、精神分裂症、肠易激综合症等在内的多种疾病。动物实验结果表明,应激能够导致神经祖细胞和新生神经元数量减少,小鼠压力反应增加、焦虑和抑郁样行为明显。母婴分离应激诱导大鼠下丘脑-垂体-肾上腺轴功能紊乱,海马区神经突触生长受损,神经可塑性受到抑制。生命早期应激对个体神经发育的影响是深刻而又广泛的,且这种影响将持续到成年,乃至生命晚期。
个体神经发育的过程主要包括增殖、分化、突触形成及髓鞘化(myelination),髓鞘(myelin)的正常生成是神经系统发育成熟的重要标志。为确保动作电位沿神经元轴突的高速与定向传导,成熟的少突胶质细胞围绕着轴突产生髓鞘。髓鞘成分大多具有抗原性,如:髓鞘碱性蛋白(myelin basic protein,MBP)、髓鞘相关糖蛋白(myelin-associatedglycoprotein,MAG)、髓鞘少突胶质细胞糖蛋白(myelin oligodendrocyte glyco-protein,MOG)等。髓鞘可以由神经元活动动态调节分化生成,并在发育后继续参与塑造神经系统。髓鞘生成的关键转录因子SOX10能够使神经前体细胞转变为少突胶质前体细胞,促进少突胶质前体细胞分化为少突胶质细胞。而MYRF则是少突胶质细胞分化和髓鞘维持的关键转录因子,是调控少突胶质细胞下游信号通路的一个关键效应器。生命早期抗生素类用药导致小鼠前额叶皮层中髓鞘相关基因过度表达,成年后出现认知异常和焦虑行为。母婴分离应激下,新生大鼠出现髓鞘阻滞现象并进而导致认知行为缺陷。髓鞘的适时及适量生成可保证神经兴奋沿神经纤维传导的速度,预防情绪障碍及认知缺陷。保护幼年髓鞘正常生成对个体正常生长发育、调节感觉和认知功能方面至关重要。
作为一种膳食补充剂,益生菌已被消费者广泛接受。目前,大部分关于益生菌功能的研究都集中在改善肠道功能、调节代谢和免疫等方面。随着“脑-肠轴”理论的逐渐成熟,通过益生菌及其代谢产物来调节肠道菌群进而改善神经功能,成为预防及治疗神经系统疾病的一种新的手段,某些双歧杆菌对神经功能的调节作用也已被动物研究和临床研究所证实。短双歧杆菌是一类革兰氏阳性、不运动、兼性厌氧的乳酸菌。许多研究表明,短双歧杆菌(B.breve)是婴幼儿肠道中的优势双歧菌种。短双歧杆菌作为在婴幼儿的生命早期定植的一类益生菌,能促进肠道菌群形成、调节代谢等功能。双歧杆菌在调控神经生理功能方面也有一些报道,例如在成年个体中显示出抗抑郁、缓解压力等功效症的功能。然而,尚未有证据表明神经元髓鞘化在抑郁症发生、发展中存在推动作用,神经元髓鞘化异常也并非抑郁症的病理特征之一。此外,尚未有关于双歧杆菌通过母体干预来调节子代神经系统髓鞘化、进而影响子代神经发育功能的报道。
发明内容
本发明提供了短双歧杆菌(Bifidobacterium breve)CCFM1025在制备预防和/或缓解母婴分离应激导致的髓鞘发育异常的产品中的应用;所述短双歧杆菌CCFM1025于2018年6月11日保藏于广东省微生物菌种保藏中心,保藏编号为GDMCC No.60386,已公开于公开号为CN108949640B的专利中。
在一种实施方式中,所述产品包括但不限于药物、功能性食品、发酵食品、营养补充剂、食品添加剂或保健品。
在一种实施方式中,所述产品中短双歧杆菌CCFM1025的含量≥1×109CFU/g或1×109CFU/mL。
在一种实施方式中,所述产品是使用短双歧杆菌CCFM1025发酵生产制得的发酵食品,所述发酵食品包括固态食品、液态食品、半固态食品。
在一种实施方式中,所述发酵食品包括乳制品、豆制品、果蔬制品;所述乳制品包括牛奶、酸奶油、干酪;所述果蔬制品包括黄瓜、胡萝卜、甜菜、芹菜、圆白菜制品。
在一种实施方式中,所述产品的施用对象为母体。
在一种实施方式中,所述母体包括但不限于处于备孕期、妊娠期或哺乳期的雌性哺乳动物。
在一种实施方式中,所述应用是预防和/或缓解子代因分离应激导致的髓鞘发育异常。
在一种实施方式中,所述应用是预防和/或缓解子代在生命早期因分离应激导致的髓鞘发育异常。
在一种实施方式中,所述髓鞘发育异常包括但不限于前额叶MYRF、SOX10、MAG、MOG、MBP中至少一种基因的表达量异常升高。
在一种实施方式中,所述应用还包括调节情绪异常、保护认知和记忆能力、促进胃肠蠕动、恢复肠道神经纤维正常释放肠脑肽的能力。
有益效果:本发明提供了短双歧杆菌CCFM1025在在预防和/或缓解母婴分离应激导致的髓鞘发育异常中的新用途通过妊娠期母体干预,利用母婴垂直传递模式,有效地调节生命早期子代哺乳动物大脑髓鞘的正常生成,改善应激障碍和认知缺陷,调节肠道正常蠕动,修复肠道神经纤维正常释放肠脑肽的能力。本发明拓展了短双歧杆菌作为益生菌的应用范围,对于深入挖掘益生菌的功能,开发具有更高保健价值的益生菌具有十分重要的意义,也为利用膳食策略预防神经系统疾病开辟出新的途径和解决方案。
附图说明
图1为小鼠在行为学实验中的表现。(A)强迫游泳实验;(B)新物体识别指数;其中*P<0.05,**P<0.01,***P<0.001。
图2为短双歧杆菌CCFM1025对小鼠中枢神经系统中少突胶质细胞发育的影响。SOX10、MYRF是少突胶质细胞成熟的关键转录因子,这些基因的表达可以作为细胞特定发育阶段的指标。(A)前额叶中SOX10 mRNA的表达量;(B)前额叶中MYRF mRNA的表达量;其中*P<0.05。
图3为短双歧杆菌CCFM1025对小鼠中枢神经系统中髓鞘生成的影响。(A)前额叶中MAG mRNA的表达量;(B)前额叶中MOG mRNA的表达量;(C)前额叶中MBP mRNA的表达量;其中*P<0.05。
图4为短双歧杆菌CCFM1025对小鼠肠道蠕动反射的影响。(A)首粒黑便;(B)粪便含水率;其中*P<0.05,***P<0.001,****P<0.0001。
图5为短双歧杆菌CCFM1025对小鼠肠道神经系统发育的影响。(A)结肠c-fos的相对表达;(B)结肠P物质的含量。其中,*P<0.05,**P<0.01。
图6为短双歧杆菌CCFM1025对小鼠肠道神经系统髓鞘化的影响。(A)结肠中SOX10mRNA的表达量;(B)结肠中MYRF的mRNA的表达量。其中,*P<0.05,**P<0.01。
具体实施方式
本发明的短双歧杆菌CCFM1025具有以下生物学特性:
(1)菌体特征:呈革兰氏染色阳性,不形成孢子,不运动的细菌。
(2)菌落特征:菌落呈乳白色,圆形,边缘整齐,微凸起,不透明,表面湿润光滑;
(3)生长特性:该菌株的最低生长温度为15℃,最高生长温度为45℃,在温度35-37℃下生长最佳,最适生长PH为6.5,培养18h后进入稳定期;
(4)在生命早期应激小鼠模型中能够显著改善小鼠的行为学表现;
(5)在生命早期应激小鼠模型中能够调节髓鞘化,促使小鼠神经系统中髓鞘正常生成,保护神经发育;
(6)在生命早期应激小鼠模型中能够显著调节肠道蠕动反射;
(7)在生命早期应激小鼠模型中能调节肠道神经功能。
实施例1:短双歧杆菌CCFM1025能改善应激小鼠的行为异常
取8周龄的C57BL/6J雌雄小鼠各20只,适应环境一周后,按1:1自由同居交配5天,交配期间减少扰动。5天后,20只母鼠另居分组。动物分组及处理方法见表1。
表1动物实验分组及处理方法
母婴分离模型:在子鼠出生后2至21天,每天进行连续3h的母婴分离应激。在8:30、9:00、9:30、10:15、10:30或11:00随机时间点开始,尽量减少幼鼠习惯化。将各笼幼鼠取出放在新的笼盒里,并转移到其他房间,3h后再将它们放回有对应母鼠的笼子里;空白对照组的幼鼠在断奶前保持不受干扰。
乳酸菌灌胃剂:取活化2代的短双歧杆菌CCFM1025于37℃下培养24h,于4℃、8000r/min离心3min收集菌体,弃去上清并用10%灭菌脱脂乳液重悬菌体,使菌浓度达到5×109CFU/mL。灌胃体积为0.2mL/只/天。
子代离乳后,停止每日的母婴分离应激,同时对所有小鼠进行行为学测试。包括强迫游泳实验和新物体识别试验。
强迫游泳具体实施方法为实验桶内装有大约20cm高的清水,水温在24±1℃左右,在正式实验前24h,每只小鼠均进行10min的游泳训练测试。正式实验时,每只小鼠进行6min测试,同时进行录像,记录小鼠的漂浮不动(immobility)时间,即四肢不动或仅后肢轻微运动。
实验结果如图1(A),早期应激诱导小鼠放弃挣扎,静止漂浮时间显著变长,小鼠出现焦虑抑郁样行为,而孕期CCFM1025干预能缓解这类情绪异常。
新物体识别:在习惯化阶段,将一只测试小鼠放在场中,让它探索2min。在习惯化之后,两个尺寸相似但形状和颜色不同的物体放置在箱内相对的角落,距离侧壁5cm,然后测试小鼠被放置在场的中心,并被允许探索包括两个物体的竞技场5min。3h后,一个物体被另一个新的物体代替,这个新的物体与先前的物体大小相似,但形状和颜色不同。然后,同样的测试小鼠被放在中心,并被允许探索场地和两个物体5min。记录小鼠对新、旧物体的探索时间及次数。识别指数(recognition index)=新物体探索时间/(新物体探索时间+旧物体探索时间)。
实验结果如图1(B)所示,应激小鼠对新物体的认知记忆能力受损,而母体服用CCFM1025能够保护其子代认知记忆的正常发育。
实施例2:短双歧杆菌CCFM1025能显著恢复生命早期髓鞘的正常发育
实施例1中的子代小鼠于第六周末安乐处死,取小鼠脑组织,并于冰上分离前额叶皮质。分别取一定质量的新鲜前额叶皮质组织加入1mL TRIzol和两颗锆珠,组织匀浆。常规方法提取总RNA。调整反转录体系浓度至1μg/μL,纯度(A260/A280)范围在1.8-2.0。反转录合成cDNA,并进行实时定量PCR反应。用荧光染料SYBR Green super mix混合样本,PCR体系为5μL mix、1μL cDNA、0.5μL正向和反向引物,用dd水补至总体积为10μL。在实时荧光定量基因扩增仪器CFX384TMReal-Time System(Bio-Rad,USA)上进行检测,每个样本设立3个平行孔,并以管家基因GAPDH为内参。所用引物序列如表2所示。反应结束后,取各个扩增循环数(Cq)进行计算分析;相对表达量以目的基因对于管家基因的倍数(2-ΔΔCq)表示,其中-ΔΔCq=(Cq目的基因-Cq管家基因)实验组-(Cq目的基因-Cq管家基因)对照组。
本实验为双因素设计,为控制比较变量单因素,这里以“空白-应激”组作为上述计算公式中的“对照组”,探究“空白-空白vs空白-应激”、“空白-应激vs CCFM1025-应激”之间的生物学差异(均采用非配对T检验)。由于“CCFM1025-空白”不作为比较因素,故图中不显示。
实验结果如图2所示,应激小鼠前额叶的少突胶质前体细胞及少突胶质细胞生成髓鞘的关键转录因子MYRF、SOX10的mRNA水平显著提高,应激诱导髓鞘化水平显著升高;此外MAG、MOG、MBP的mRNA水平显著提高(图3),表明髓鞘异常过度发育,而CCFM1025干预能保护髓鞘正常生成,促进神经正常发育。
实施例3:短双歧杆菌CCFM1025对应激小鼠肠道蠕动反射的调节作用
实施例1中的子代小鼠于第六周周进行肠道动力检测实验。具体包括首粒黑便实验、粪便含水率实验。
首粒黑便试验:称取阿拉伯胶100g,加入800mL水,混合均匀后加热煮沸至透明,再加入活性炭50g,重新煮沸3次。待溶液冷却后,用水稀释定容至1L,即可得墨汁。每只小鼠灌胃0.2mL墨汁,记录开始灌胃墨汁时间至排出首粒黑便的时间。
粪便含水率试验:将每只小鼠单独放置在笼盒中,将收集到的粪便装入无菌的1.5mL EP管中,冰盒中保存,收集期间记录每只小鼠的排便粒数,粪便湿重。冷冻干燥后,记录干重,粪便含水率计算公式为:粪便含水率(%)=(粪便湿重-粪便干重)/粪便湿重。
实验结果如图4所示,应激导致小鼠排出首粒黑便时间变长,肠道蠕动减缓,粪便中水分含量降低。而CCFM1025干预可以发挥调节肠道正常蠕动的作用。
实施例4:短双歧杆菌CCFM1025对应激小鼠肠神经功能的影响
实施例1中的子代小鼠于第六周末安乐处死,收集结肠组织,RNA的提取、反转录及c-fos实时定量PCR实验参考实施例2。所用引物序列如表2所示。另取结肠组织,1:9加入预冷PBS,制备组织匀浆液,用ELISA试剂盒检测结肠SP的含量。
c-fos可表征神经元的激活状态,但应激小鼠的结肠c-fos的mRNA表达异常降低,CCFM1025干预可以发挥调节肠神经正常活动的功能(图5A)。P物质(SP)是广泛分布于神经纤维内的一种神经肽,当神经受到刺激,P物质可在神经末梢释放。应激损伤了肠道神经纤维正常释放肠脑肽的能力,而短双歧杆菌1025干预可起到修复作用(图5B)。
实施例5:短双歧杆菌CCFM1025对肠道髓鞘化的调节作用
为了验证CCFM1025对肠道神经髓鞘化的影响,实施例1中的子代小鼠于第六周末安乐处死,取结肠组织,参考实施例2进行组织RNA的提取及qRT-PCR反应。所用引物序列如表2所示。实验结果如图6所示,CCFM1025干预可以恢复应激下异常升高的髓鞘化相关mRNA的表达,减轻生命早期应激下的结肠髓鞘过度生成。
表2 qPCR引物序列
实施例6:利用本发明短双歧杆菌CCFM1025制造含该菌的发酵食品
选用新鲜蔬菜洗净后榨汁,接着进行高温瞬间灭菌,在温度140℃下高温热杀菌2秒后,立即降温至37℃,再接入本发明制备的短双歧杆菌CCFM1025菌剂发酵剂,使其浓度达到108CFU/mL以上,在温度4℃下冷藏保存,于是得到含有本发明短双歧杆菌CCFM1025活菌的果蔬饮料。
利用本发明能够使用短双歧杆菌CCFM1025发酵生产制备其他发酵食品,所述发酵食品包括固态食品、液态食品、半固态食品。所述发酵食品包括乳制品、豆制品、果蔬制品,所述乳制品包括牛奶、酸奶油、干酪;所述果蔬制品包括黄瓜、胡萝卜、甜菜、芹菜、圆白菜制品。
所述发酵食品能够减轻生命早期应激下神经发育异常,抑制神经系统过度髓鞘化,保护情绪、认知、胃肠道蠕动的功能。
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。
Claims (4)
1.短双歧杆菌(Bifidobacterium breve)CCFM1025在制备预防母婴分离应激导致的子代髓鞘发育异常的药物中的应用;所述短双歧杆菌CCFM1025的保藏编号为GDMCCNo.60386;所述药物的施用对象为母体。
2.根据权利要求1所述的应用,其特征在于,所述药物中短双歧杆菌CCFM1025的含量≥1×109CFU/g或1×109CFU/mL。
3.根据权利要求1所述的应用,其特征在于,所述母体包括处于备孕期或妊娠期的雌性哺乳动物。
4.根据权利要求1~3任一所述的应用,其特征在于,所述药物同时具有调节情绪异常、保护认知和记忆能力、促进胃肠蠕动、恢复肠道神经纤维正常释放P物质的能力。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210265577.XA CN114533765B (zh) | 2022-03-17 | 2022-03-17 | 短双歧杆菌ccfm1025在调节幼年神经发育中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210265577.XA CN114533765B (zh) | 2022-03-17 | 2022-03-17 | 短双歧杆菌ccfm1025在调节幼年神经发育中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114533765A CN114533765A (zh) | 2022-05-27 |
CN114533765B true CN114533765B (zh) | 2023-08-25 |
Family
ID=81663723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210265577.XA Active CN114533765B (zh) | 2022-03-17 | 2022-03-17 | 短双歧杆菌ccfm1025在调节幼年神经发育中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114533765B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115590889A (zh) * | 2022-10-11 | 2023-01-13 | 江南大学(Cn) | 一种调节生物昼夜节律的短双歧杆菌及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107853705A (zh) * | 2012-11-02 | 2018-03-30 | N·V·努特里奇亚 | 用于改善大脑的合生素组合物 |
CN108949640A (zh) * | 2018-08-22 | 2018-12-07 | 江南大学 | 短双歧杆菌ccfm1025、其发酵食品及其应用 |
JP2021023257A (ja) * | 2019-08-08 | 2021-02-22 | 森永乳業株式会社 | 分離不安障害の予防又は改善のための組成物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220290095A1 (en) * | 2018-08-22 | 2022-09-15 | Jiangnan University | Bifidobacterium breve CCFM1025, Food Fermented Thereby and Application Thereof |
-
2022
- 2022-03-17 CN CN202210265577.XA patent/CN114533765B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107853705A (zh) * | 2012-11-02 | 2018-03-30 | N·V·努特里奇亚 | 用于改善大脑的合生素组合物 |
CN108949640A (zh) * | 2018-08-22 | 2018-12-07 | 江南大学 | 短双歧杆菌ccfm1025、其发酵食品及其应用 |
JP2021023257A (ja) * | 2019-08-08 | 2021-02-22 | 森永乳業株式会社 | 分離不安障害の予防又は改善のための組成物 |
Non-Patent Citations (1)
Title |
---|
E O'Sullivan.BDNF expression in the hippocampus of maternally separated rats: does Bifidobacterium breve 6330 alter BDNF levels?.Benef Microbes .2011,第199-207页. * |
Also Published As
Publication number | Publication date |
---|---|
CN114533765A (zh) | 2022-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nishida et al. | Daily administration of paraprobiotic Lactobacillus gasseri CP2305 ameliorates chronic stress-associated symptoms in Japanese medical students | |
CN112972502B (zh) | 短双歧杆菌ccfm1025在缓解阿尔兹海默症中的应用 | |
RU2704133C2 (ru) | Применение lactobacillus paracasei для усиления восстановления разнообразия кишечной микрофлоры после дисбактериоза | |
JP2020026437A (ja) | 長寿促進のための、パラカゼイ gks6の活性物質、それを含む組成物、およびその使用 | |
CN113215034B (zh) | 一株能够缓解阿尔兹海默症并增加粪便乙酸含量的短双歧杆菌及其应用 | |
CN114533765B (zh) | 短双歧杆菌ccfm1025在调节幼年神经发育中的应用 | |
CN115089715B (zh) | Alpk1基因作为中枢神经系统疾病预防或治疗靶点的应用 | |
CN114540245A (zh) | 一株同时具有缓解抑郁情绪及促进肠道分泌IgA功能的鼠李糖乳杆菌CCFM1228及其应用 | |
CN116270756A (zh) | 嗜黏蛋白阿克曼氏菌及其药物组合物在改善和治疗神经退行性疾病中的应用 | |
CN114262677A (zh) | 一种植物乳杆菌及其在预防和/或治疗炎症性肠病中的应用 | |
CN108064944A (zh) | 一种调节肠道菌群的益生菌饮料及其制备方法 | |
CN114533766B (zh) | 长双歧杆菌婴儿亚种ccfm687在调节神经细胞髓鞘化中的应用 | |
CN117264810A (zh) | 一种具有改善代谢综合征功能的益生菌组合物及其应用 | |
CN106102755B (zh) | 用于产生视黄酸的试剂 | |
CN113509495B (zh) | 鼠李糖乳杆菌在缓解肠道炎症中的应用 | |
CN115039876A (zh) | 一种用于预防和/或治疗脑白质营养不良的功能性食品 | |
CN115838653A (zh) | 一种改善不良情绪的植物乳杆菌gm11及其用途 | |
CN114196599A (zh) | 一种用于肠道菌群调和的微生物组合物及其制备方法 | |
CN115590889A (zh) | 一种调节生物昼夜节律的短双歧杆菌及其应用 | |
CN111603489A (zh) | 一种改善便秘的菌剂及其制备方法 | |
US11779616B1 (en) | Method of improving memory and learning ability | |
CN118104826A (zh) | 一种用于改善神经发育和功能障碍的低聚糖组合物 | |
CN114601919B (zh) | 一种抗氧化、助眠组合物及其应用 | |
CN109536424A (zh) | 一种短乳杆菌及其应用 | |
CN118105395A (zh) | 低聚糖2’-fl在制备用于改善神经发育和改善功能障碍的产品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |